Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

37.5%

3 terminated/withdrawn out of 8 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 3 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 1

7(87.5%)

Phase 2

1(12.5%)

8Total

Phase 1(7)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT07228078Phase 2Recruiting

Open-Label Extension Protocol to SNK01-AD01 Study

Role: lead

NCT06189963Phase 1Recruiting

Clinical Study of SNK01 in Participants With Moderate Alzheimer's Disease

Role: lead

NCT05990920Phase 1Completed

Study of Allogeneic Blood-derived Natural Killer Cells to Evaluate Safety and Tolerability in Cancer Refractory to Conventional Therapy

Role: lead

NCT05099549Phase 1Terminated

Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With SNK01 in Subjects With Advanced/Metastatic EGFR-Expressing Cancers

Role: lead

NCT04678453Phase 1Terminated

Safety of SNK01 in Subjects With Alzheimer's Disease (ASK-AD)

Role: lead

NCT03941262Phase 1Completed

Safety of SNK01 in Subjects With Pathologically Confirmed Metastatic and/or Unresectable Cancer Refractory to Conventional Therapy

Role: lead

NCT04464967Phase 1Withdrawn

Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers

Role: lead

NCT03894579Phase 1Completed

Autologous Natural Killer Cells in Subjects With Plaque Psoriasis

Role: lead

All 8 trials loaded